Gilead to supply TRODELVY for prospective, pan-tumor trial

Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH^TM ) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer. 

Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. Several types of biomarkers are being evaluated, including quantitative RNA and multivariate algorithms that may optimize the use of different anti-cancer therapies. These biomarkers can be analyzed in parallel with the genomic mutations assessed by comprehensive genomic profiling (CGP), thus maximizing the information available from often limited tumor tissue samples.

“As the first diagnostics company to run its own prospective interventional trial to show the utility of its tests, Strata is honored to have the support and collaboration of forward-thinking biopharma companies like Gilead Sciences for the Strata PATH trial,” said Dan Rhodes, Ph.D., Chief Executive Officer and co-founder, Strata Oncology. “Quantitative RNA and multivariate biomarkers have the potential to optimize the use of expression-based therapies and improve the outcomes and the quality of life for cancer patients.”